Summary It is important that the introduction of breast screening is closely monitored. The anticipated effect on breast cancer mortality will take 10 years or more fully to emerge, and will only occur if a succession of more short-term end points are met. Data from the Swedish two-county randomised trial provide targets that should be achieved, following a logical progression of compliance with the initial invitation, prevalence and stage distribution at the prevalence screen, the rate of interval cancers after the initial screen, the pick-up rate and stage distribution at later screening tests, the rate of interval cancers after later tests, the absolute rate of advanced cancer and finally the breast cancer mortality rate. For evaluation purposes, historical data on stage at diagnosis is desirable; it is suggested that tumour size is probably the most relevant variable available in most cases.
Screening for breast cancer is being introduced in Britain on the recommendation of the Forrest Report. Experience from the cervical cancer screening programme has demonstrated that the performance of a national programme may fall below expectation based on experience from specialist UK centres, or from other countries. It is therefore important to monitor the performance of the national breast cancer screening programme from its inception, to determine how closely the benefits it achieves approach the benefits seen in the randomised trials and population demonstration projects, the results of which formed the basis for the Forrest Report's recommendation.
The most relevant of the trials which have so far reported results is the Swedish two-county study (Tabar et al., 1985) , for a number of reasons. It used mammography as the sole screening modality, and for the age group of relevance, women aged 50-64 years, the average inter-screening interval (33 months) was similar to the 3-year interval to be adopted in Britain. It also screened over 30,000 women in this age group, compared to the 15,000 or fewer screened in Florence (Palli et al., 1986) , Nijmegen (Verbeek et al., 1984) or Utrecht (de Waard et al., 1984) . It is thus of interest to examine the different evaluation measures that emerged from the Swedish study, to identify the information on which these measures are based and at what stage in the trial this information became available. The emphasis in this paper is on the fundamental effect measure, breast cancer mortality. Measures relating to other important aspects of the screening programme, for example costs, quality of care or the value of different diagnostic procedures, are not considered.
Results of the Swedish two-county study
The three main criteria one can use in evaluating the effect of the screening programme are: (1) changes in mortality; (2) changes in the absolute rate of advanced disease; (3) parameters of the screening process, comprising both the screening test and the further diagnostic procedures applied to women positive on the screening test -these parameters include sensitivity, specificity, the distribution of lead time (the length of time diagnosis is advanced by screening) and sojourn time (the length of time preclinical lesions are detectable by screening), and the predictive value for malignancy.
Mortality of course is the basic evaluation measure. In the Swedish study, however, no difference between the study and control group was seen until the fourth year. It was not until the end of the seventh year that the gap had widened sufficiently, and adequate numbers accrued, for one to be satisfied that breast cancer mortality had been reduced. Similarly, in Utrecht (Collette et al., 1984) and Nijmegen (Verbeek et al., 1984) , at least 7 years elapsed after the start of screening before the effect on mortality was able to be assessed. Although similar evaluation will be necessary in this country, 7 years or more is a long time to wait before one can determine whether the programme is effective. Earlier measures are required.
The effect on mortality is the result of earlier diagnosis, which is seen in the reduction in 4he rate of advanced disease. This reduction in advanced disease, if it occurs, will be detectable earlier than the reduction in mortality. Figure  1 gives the corresponding results for advanced disease ( Figure la ) and breast cancer deaths (Figure lb) for the group aged 50-59 years at study entry from the two-county study. One can see that the gap between the two curves begins to appear some 2 years earlier for the advanced cancers than for the deaths. The reduction in advanced disease results from earlier diagnosis and so depends on the lead time distribution of cases diagnosed by screening. This distribution expresses quantitatively the length of time by which diagnosis has been advanced. It is reflected in the incidence of interval cancers among screened women in the years following a negative screening test (Day & Walter, 1984) . To be informative, the incidence of interval cancers needs to be expressed as a proportion of the incidence that would have been expected in the absence of screening, as shown in Figure 2 from the two-county study (Tabar et al., 1987a) .
The difference between the incidence rate of interval cancers and the rate expected in the absence of screening reflects the number of cancers with a diagnosis that was advanced to the previous screening test. An initial indication of the incidence rate of interval cancers (i.e. as in Figure 2 ) is therefore given by the prevalence rate of cancers detected at the first screen. As with interval cancers, this rate is more informatively expressed if divided by the incidence rate expected in the absence of screening in women presenting for screening. Results from the two-county study are given in Table I are diagnosed at an earlier stage. Table II gives the proportion of stage II or worse of cancers detected at the first screen, of interval cancers, of cancers detected at the second or later screen, and of cancers seen in the control group (Tabar et al., 1987) . The similarity of the interval and the control group cancers is striking. Table II also gives the size distribution of screen-detected cancers and of cancers diagnosed in the control group. That the screen-detected cancers should have a more favourable stage distribution and be of smaller size is a prerequisite for the subsequent deficit of advanced cancers in the group allocated to screening, necessary but not sufficient. Finally, the effect of the programme on the subsequent rates of advanced disease and mortality will depend directly on the proportion of the target population who present for screening. Compliance rate is clearly an important initial measure -necessary but not sufficient -of programme effectiveness. In the Swedish two-county study, compliance in the age group 50-64 was of the order of 90%.
Implications for the information requirements of a regional and national evaluation system
The foregoing description of the process whereby screening leads to a reduction in breast cancer mortality pinpoints the information required to determine whether the programme is on course. Table III summarises a minimum set of measures that an information system should monitor to evaluate the effectiveness of the programme in reducing severity of and mortality from the disease. The first three measures (compliance, screening characteristics and rate of advanced cancers) are not in themselves sufficient to demonstrate a reduction in mortality. A favourable value for each of these measures is necessary, however, if an acceptable effect on breast cancer mortality is to be achieved. Poor performance indicates where remedial action is required. The information required to monitor these performance measures is described below.
Compliance rate It is important that the real compliance rate is measured, i.e. the proportion who present for screening among the women invited who are both alive and resident in the catchment population. One needs to ascertain the accuracy of the population lists that are used.
Characteristics of the screening procedures Prevalence rate at the first screen This measure should be by 5-year age group, since rates increase rapidly with age. One has the approximate relationship: Prevalence rate at first screen sensitivity x average sojourn Expected incidence rate time This expression indicates that to be informative in terms of the underlying screening parameters, and so for comparison with other programmes, the prevalence rate needs to be expressed as a multiple of the expected annual incidence rate in screened women (i.e. the rate one would have seen in the absence of screening). This incidence rate is not directly observable, but it can be derived from the expected rate in the total population and the rate in non-attenders. The rate in non-attenders is directly observable provided that the population is covered by cancer registration of high quality, and that the non-attenders are well identified. For the latter one needs to know, among the women who were invited but did not attend, the proportion alive and living in the catchment area (as for the assessment of compliance).
Estimates of the rate in the total population, which is not directly observable, can be obtained either from rates in comparable, neighbouring unscreened populations or from historical incidence data. Both require cancer registration and the latter requires the existence of good quality cancer registration in previous years. The expected rate among the attenders is then obtained from the identity:
Incidence rate in total population =Pxincidence rate in attenders + (1 -P) x incidence rate in refusers where P is the real compliance rate (expressed as a proportion).
Incidence of interval cancers Registration of interval cancers requires coverage of the population by good cancer registration. As noted before, it is important to express the rate of interval cancers as a proportion of the expected rate in the screened group, which requires the expected incidence rate in the total population and the incidence rate among non-attenders.
Comparison of the interval cancer rates and the initial prevalence rates with those seen in the two-county study will indicate whether the following parameters of the screening process (i.e. screening test and associated diagnostic procedures) are comparable to those seen in an effective programme: (1) sensitivity; (2) distribution of sojourn time and lead time; (3) 'overdiagnosis' of breast cancer -this appeared to be absent from the two-county study (Day et al., 1988) , but has been suspected elsewhere. It would be surprising if comparable values for sensitivity and the sojourn time distribution did not lead to comparable effects on mortality and advanced disease.
Stage distribution of screen detected cancers As can be seen from Table II, the stage distribution of cancers detected at the first screen may differ from that seen at later screens. The definition of stage needs to take account of the information likely to be available in the majority of cases. Tumour size may be an acceptable substitute for stage, as discussed in the next section. The stage (or tumour size) distribution of screen detected cancers needs to be compared to the stage distribution one would have expected in the absence of screening among women who presented for screening. This latter distribution can be obtained from the stage distribution of cancers among non-attenders and that of cancers in the total population before the start of the programme. (1) tumour size is of strong prognostic value in its own right; (2) the proportion with positive nodes is strongly related to tumour size and this relationship is the same in screen detected as in clinically detected cases (Tabar et al., 1987b) . This last point suggests that screen detected small cancers are similar in behaviour to clinically detected small cancers. If tumour size is used, it can either be dichotomised at say 15 or 20mm, to give 'early' and 'advanced' cancers, or subdivided more finely. The first approach is simpler and may prove equally informative. 
Conclusions
The scheme for an information system described above is shown in Table IV with the time sequence in Figure 3 . It follows the process of screening from the start, the identification of the target population, to the final evaluation measure, the effect on breast cancer mortality. The information measures described plot the course that the programme has to follow to achieve the results on breast cancer mortality expected from the Swedish randomised trial. Table V proposes minimum levels of performance for each of these measures. The only aspect not considered is treatment; it is clear that a reduction in mortality will result from the achievement of earlier diagnosis only if the early lesions are adequately treated. Figure 3 
